Patents by Inventor Fumihiko Saitoh

Fumihiko Saitoh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200358323
    Abstract: A motor includes a rotor and a stator. The stator is formed by laminating a plurality of magnetic thin strips each having a plurality of teeth parts. The magnetic thin strip includes an elliptical-shaped inner diameter part formed along tip end portions of the plural teeth parts. At least one magnetic thin strip in the laminated magnetic thin strips is shifted by a given angle with respect to other magnetic thin strips in a horizontal direction, and positions of all teeth parts of the laminated magnetic thin strips correspond to one another to reduce cogging torque.
    Type: Application
    Filed: April 1, 2020
    Publication date: November 12, 2020
    Inventors: MITSUO SAITOH, NAOKI NOJIRI, HIDEAKI HAMADA, KENJI TANIMOTO, FUMIHIKO KAWAI, YUKIO NISHIKAWA
  • Publication number: 20200308136
    Abstract: Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.
    Type: Application
    Filed: September 13, 2018
    Publication date: October 1, 2020
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Yuji KAWADA, Fumihiko SAITOH, Hiroshi NAGASUE, Tsutomu SATOH
  • Publication number: 20200239419
    Abstract: An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)?(D-TA): in which p represents an integer of 0 to 4; R1 each independently represent a halogen atom, a cyano group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a hydroxy C1-6 alkyl group, a cyanated C1-6 alkyl group, a halogenated C1-6 alkoxy group, a C1-6 alkoxy C1-6 alkyl group, a mono-/di-C2-7 alkanoyl amino group, a carboxamide group, or a C1-6 alkoxy carbonyl group; and R2a and R2b each independently represent a C1-6 alkyl group.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 30, 2020
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Yuji KAWADA, Fumihiko SAITOH, Hiroshi NAGASUE
  • Patent number: 10669239
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 2, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Hiroshi Nagasue
  • Publication number: 20190337897
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Application
    Filed: July 17, 2019
    Publication date: November 7, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko SAITOH, Hiroshi NAGASUE
  • Patent number: 10399945
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 3, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Hiroshi Nagasue
  • Patent number: 10201531
    Abstract: The present invention provides a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. A compound having Nrf2 activation ability is provided by the present invention.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 12, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Tomoyuki Kamino, Motoi Nakahara
  • Publication number: 20190023657
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Application
    Filed: September 21, 2018
    Publication date: January 24, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko SAITOH, Hiroshi NAGASUE
  • Publication number: 20180228776
    Abstract: The present invention provides a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. A compound having Nrf2 activation ability is provided by the present invention.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko SAITOH, Tomoyuki KAMINO, Motoi NAKAHARA
  • Patent number: 9453015
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: September 27, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro Okano, Fumihiko Saitoh
  • Publication number: 20150166536
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Application
    Filed: February 25, 2015
    Publication date: June 18, 2015
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro OKANO, Fumihiko SAITOH, Muneyoshi MAKABE, Kouki OGAWA
  • Patent number: 8987242
    Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: March 24, 2015
    Assignees: Merck Sharp & Dohme Corp., Mochida Pharmaceuticals Co., Ltd.
    Inventors: Samuel Chackalamannil, Tin-Yau Chan, Mariappan V. Chelliah, Martin C. Clasby, Michael Dwyer, William J. Greenlee, Tomokazu Hirabayashi, Santhosh Neelamkavil, Hidemitsu Nishida, Fumihiko Saitoh, Unmesh Shah, Yan Xia
  • Patent number: 8642582
    Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: February 4, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hidemitsu Nishida, Fumihiko Saitoh, Tomokazu Hirabayashi, Samuel Chackalamannil, Tin-Yau Chan, Mariappan V. Chelliah, Martin C. Clasby, Michael Dwyer, William J. Greenlee, Yan Xia
  • Publication number: 20110135650
    Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: June 1, 2010
    Publication date: June 9, 2011
    Inventors: Samuel CHACKALAMANNIL, Tin-Yau CHAN, Mariappan V. CHELLIAH, Martin C. CLASBY, Michael DWYER, William J. GREENLEE, Tomokazu HIRABAYASHI, Santhosh NEELAMKAVIL, Hidemitsu NISHIDA, Fumihiko SAITOH, Unmesh SHAH, Yan XIA
  • Publication number: 20110059958
    Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: December 3, 2009
    Publication date: March 10, 2011
    Inventors: Hidemitsu Nishida, Fumihiko Saitoh, Tomokazu Hirabayashi, Samuel Chackalamannil, Tin-Yau Chan, Mariappan V. Chelliah, Martin C. Clasby, Michael Dwyer, William J. Greenlee, Yan Xia
  • Patent number: 7122662
    Abstract: This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action. The invention also relates to a pharmacophore which was derived from the compound and is useful in molecular designing of the FXa inhibitor.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: October 17, 2006
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hidemitsu Nishida, Fumihiko Saitoh, Kousuke Harada, Ikuya Shiromizu, Takafumi Mukaihira
  • Publication number: 20050148769
    Abstract: This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action. The invention also relates to a pharmacophore which was derived from the compound and is useful in molecular designing of the FXa inhibitor.
    Type: Application
    Filed: December 16, 2004
    Publication date: July 7, 2005
    Inventors: Hidemitsu Nishida, Fumihiko Saitoh, Kousuke Harada, Ikuya Shiromizu, Takafumi Mukaihira
  • Patent number: 6858599
    Abstract: This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action. The invention also relates to a pharmacophore which was derived from the compound and is useful in molecular designing of the FXa inhibitor.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: February 22, 2005
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hidemitsu Nishida, Fumihiko Saitoh, Kousuke Harada, Ikuya Shiromizu, Takafumi Mukaihira
  • Publication number: 20030045520
    Abstract: This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action.
    Type: Application
    Filed: December 27, 2001
    Publication date: March 6, 2003
    Inventors: Hidemitsu Nishida, Fumihiko Saitoh, Kousuke Harada, Ikuya Shiromizu, Takafumi Mukaihira
  • Patent number: 5220621
    Abstract: A character recognition system and method using the generalized Hough transform are disclosed. A template table which stores edge point parameters to be used for the generalized Hough transform is compressed so as to include only predetermined parameters, and is then divided into a plurality of template tables which are respectively loaded in the memories of a plurality of subprocessors operating in parallel under the control of a main processor. In performing recognition processing, these subprocessors operate in parallel according to their related partial template tables. Character recognition using the generalized Hough transform provides a high rate of character recognition. Also, parallel processing using the compressed template tables and partial template tables helps shorten table search time and computation time, thereby increasing processing efficiency.
    Type: Grant
    Filed: July 31, 1991
    Date of Patent: June 15, 1993
    Assignee: International Business Machines Corporation
    Inventor: Fumihiko Saitoh